Abivax (NASDAQ:ABVX) and Editas Medicine (NASDAQ:EDIT) Financial Review

Abivax (NASDAQ:ABVX) and Editas Medicine (NASDAQ:EDIT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Insider and Institutional Ownership

47.9% of Abivax shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 2.1% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Abivax and Editas Medicine’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	N/A	N/A
Editas Medicine	-608.88%	-200.25%	-68.57%

Earnings and Valuation

This table compares Abivax and Editas Medicine”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$190.71 million	N/A	N/A
Editas Medicine	$38.90 million	9.06	-$237.09 million	($2.85)	-1.38

Abivax has higher earnings, but lower revenue than Editas Medicine.

Risk & Volatility

Abivax has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.18, suggesting that its stock price is 118% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Abivax and Editas Medicine, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1	0	8	1	2.90
Editas Medicine	3	7	3	1	2.14

Abivax currently has a consensus price target of $102.14, suggesting a potential upside of 21.71%. Editas Medicine has a consensus price target of $5.10, suggesting a potential upside of 30.10%. Given Editas Medicine’s higher probable upside, analysts clearly believe Editas Medicine is more favorable than Abivax.

Summary

Abivax beats Editas Medicine on 6 of the 11 factors compared between the two stocks.

About Abivax

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

About Editas Medicine

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.